CULLINAN THERAPEUTICS, INC. Other Current Liabilities
CULLINAN THERAPEUTICS, INC. (CGEM) had Other Current Liabilities of $1.53 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Other Liabilities, Current $1.53M.
- 2026-03-31: Other Liabilities, Current $1.35M.
- 2025-12-31: Other Liabilities, Current $996.00K.
- 2025-09-30: Other Liabilities, Current $1.51M.
| Period end | Other Liabilities, Current |
|---|---|
| 2026-06-30 | $1.53M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.35M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $996.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $1.51M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $2.23M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $2.79M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.44M 10-K · filed 2026-03-10 |
| 2024-09-30 | $1.71M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $2.22M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.52M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $914.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.58M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $1.03M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $5.11M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $1.96M 10-K · filed 2024-03-14 |
| 2021-12-31 | $973.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |